Patents by Inventor John Moliterni

John Moliterni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7427635
    Abstract: The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: September 23, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Xin-Jie Chu, Nader Fotouhi, Nicholas J. S. Huby, Norman Kong, Lee Apostle McDermott, John Moliterni, Zhuming Zhang
  • Publication number: 20060229330
    Abstract: Novel intermediate compounds are disclosed. These compounds are useful in the synthesis of 4-aminopyrimidine-5-one derivatives that inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). The 4-aminopyrimidine-5-one derivatives and their pharmaceutically acceptable salts have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors.
    Type: Application
    Filed: June 20, 2006
    Publication date: October 12, 2006
    Inventors: David Bartkovitz, Xin Chu, Qingjie Ding, Nan Jiang, Allen Lovey, John Moliterni, John Mullin, Binh Vu, Peter Wovkulich
  • Publication number: 20060063814
    Abstract: The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.
    Type: Application
    Filed: September 14, 2005
    Publication date: March 23, 2006
    Inventors: Robert Goodnow,, Nicholas Huby, Norman Kong, Lee McDermott, John Moliterni, Zhuming Zhang
  • Publication number: 20060041146
    Abstract: The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.
    Type: Application
    Filed: August 11, 2005
    Publication date: February 23, 2006
    Inventors: Xin-Jie Chu, Nader Fotouhi, Nicholas Huby, Norman Kong, Lee McDermott, John Moliterni, Zhuming Zhang
  • Patent number: 5100903
    Abstract: This invention pertains to novel N-aryl-N-[N-substituted 3-alkoxy-4-piperidinyl]amides useful as analgesics, and methods of administering analgesia, which comprises the systemic administration to mammals of such compounds, and pharmaceutical compositions containing such compounds, wherein the novel compounds have the general formula: ##STR1## including optically active isomeric forms, cis/trans isomeric forms and the pharmaceutically acceptable acid addition salts thereof, wherein:R is an aryl group selected from the group consisting of phenyl and substituted phenyl, wherein the substituents on the phenyl group are independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, and combinations thereof;R.sub.1 is an alkyl group selected from the group consisting of lower-alkyl, lower-alkenyl, and lower-alkoxy lower-alkyl, each alkyl group having from 1 to 6 carbon atoms;R.sub.
    Type: Grant
    Filed: November 21, 1990
    Date of Patent: March 31, 1992
    Assignee: Anaquest, Inc.
    Inventors: Nhora L. Lalinde, John Moliterni, H. Kenneth Spencer
  • Patent number: 4994471
    Abstract: This invention pertains to novel N-aryl-N-[N-substituted 3-alkoxy-4-piperidinyl]amides useful as analgesics, and methods of administering analgesia, which comprises the systemic administration to mammals of such compounds, and pharmaceutical compositions containing such compounds, wherein the novel compounds have the general formula: ##STR1## including optically active isomeric forms, cis/trans isomeric forms and the pharmaceutically acceptable acid addition salts therof, wherein:R is an aryl group selected from the group consisting of phenyl and substituted phenyl, wherein the substituents on the phenyl group are independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, and combinations thereof;R.sub.1 is an alkyl group selected from the group consisting of lower-alkyl, lower-alkenyl, and lower-alkoxy lower-alkyl, each alkyl group having from 1 to 6 carbon atoms;R.sub.
    Type: Grant
    Filed: May 12, 1989
    Date of Patent: February 19, 1991
    Assignee: BOC, Inc.
    Inventors: Nhora L. Lalinde, John Moliterni, H. Kenneth Spencer
  • Patent number: 4939161
    Abstract: This invention pertains to novel substituted N-aryl-N-[1-substituted 3,5-dimethyl-4-piperidinyl]amides useful as analgesics, and methods of administering analgesia, which comprises the systemic administration to mammals of such compounds, and pharmaceutical compositions containing such compounds, wherein the novel compounds have the general formula: ##STR1## including optically active isomeric forms, cis/trans isomeric forms and the pharmaceutically acceptable acid addition salts thereof, wherein:R.sub.1 is an alkyl group selected from the group consisting of lower-alkyl, and lower-alkoxy lower-alkyl, each alkyl group having from 1 to 6 carbon atoms; andR.sub.2 is a member selected from the group consisting of phenyl lower-alkyl, pyridinyl, lower-alkyl, thienyl lower-alkyl, pyrazolyl lower-alkyl, tetrazolyl lower-alkyl, 4,5-dihydro-5-oxo-1H-tetrazolyl lower-alkyl, 1,3-dihydro-1,3-dioxo-2H-isoindolyl (N-phthalimidyl) lower-alkyl, and 2,3-dihydro-2-oxo-1H-benzimidazolyl lower-alkyl.
    Type: Grant
    Filed: May 12, 1989
    Date of Patent: July 3, 1990
    Assignee: BOC, Inc.
    Inventors: Nhora L. Lalinde, John Moliterni, H. Kenneth Spencer